Director at Turn Therapeutics (TTRX) makes bona fide gift of 300,000 shares

Rhea-AI Filing Summary

Turn Therapeutics Inc. director Arthur F. Golden reported a bona fide gift of 300,000 shares of Common Stock. The shares were transferred at a reported price of $0.0000 per share, reflecting a non-market, no‑consideration disposition. Following the gift, he directly holds 360,602 Common Stock shares.

Insider Trade Summary

300,000 shares gifted

Mixed 1 txn

Insider GOLDEN ARTHUR F

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	300,000	$0.00	--

Holdings After Transaction: Common Stock — 360,602 shares (Direct)

Footnotes (1)

Key Figures

Shares gifted: 300,000 shares Reported price per share: $0.0000 per share Shares held after transaction: 360,602 shares +2 more

5 metrics

Shares gifted 300,000 shares Bona fide gift of Common Stock

Reported price per share $0.0000 per share Gift transfer of Common Stock

Shares held after transaction 360,602 shares Director’s direct Common Stock holdings post-gift

Gift transactions 1 transaction Bona fide gift coded G in Form 4

Gifted shares total 300,000 shares GiftShares in transaction summary

Key Terms

bona fide gift, Common Stock, Form 4, transaction code G, +1 more

5 terms

bona fide gift financial

"transaction_code_description: "Bona fide gift""

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code G financial

"transaction_code: "G""

direct ownership financial

"ownership_type: "direct""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDEN ARTHUR F

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CALIFORNIA 91362

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/02/2026		G		300,000	A	$0	360,602	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Zuraiz Chaudhary, attorney-in-fact for Arthur Golden	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Turn Therapeutics (TTRX) disclose in this Form 4?

Turn Therapeutics reported that director Arthur F. Golden made a bona fide gift of 300,000 shares of Common Stock. This was a non-market transfer with no cash consideration, classified as a gift disposition rather than an open-market sale or purchase.

How many Turn Therapeutics (TTRX) shares did the director gift?

Arthur F. Golden gifted 300,000 shares of Turn Therapeutics Common Stock. The filing classifies the transaction under code G, described as a bona fide gift, indicating the shares were transferred without payment at a reported price of $0.0000 per share.

What is Arthur F. Golden’s Turn Therapeutics (TTRX) shareholding after the gift?

After the reported gift, Arthur F. Golden directly holds 360,602 shares of Turn Therapeutics Common Stock. This post-transaction figure reflects his remaining direct ownership as disclosed, with no derivative securities listed in the filing’s derivative holdings summary.

Was the Turn Therapeutics (TTRX) insider transaction a market sale or purchase?

The transaction was not a market sale or purchase. It is coded G in the filing, meaning a bona fide gift, with 300,000 Common Stock shares transferred at a reported price of $0.0000 per share, indicating no cash proceeds from the transfer.

Who carried out the reported insider transaction at Turn Therapeutics (TTRX)?

The reported transaction was carried out by Arthur F. Golden, a director of Turn Therapeutics Inc. The Form 4 shows he disposed of 300,000 Common Stock shares via a bona fide gift and now directly owns 360,602 shares following the transaction.